As shown in Fig. 2A and Table 2, the serum EFNA1 and MMP13 levels of GC patients in the training cohort were higher than those in the normal controls, which was confirmed by statistics (P < 0.001). The gene discussed is EFNA1; the disease is gastric cancer.